Inflarx drops lead program targeting C5a in rare skin disorder

After multiple setbacks, a futility analysis in pyoderma gangrenosum has led Inflarx to discontinue C5a mAb vilobelimab. The biotech’s shares fell 60% Wednesday, closing at $0.73 and losing $65 million in market cap based on 59.4 million shares outstanding.

The decision was based on data from 30 patients, in whom no unexpected adverse events were noted at the interim analysis. Inflarx N.V. (NASDAQ:IFRX) had been exploring use of the mAb for a variety of indications; it previously missed the primary endpoint in a Phase IIb trial to treat hidradenitis suppurativa...